Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
- Conditions
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 695
- Registration Number
- NCT02229396
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT02223065
Dapagliflozin in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Medical University Innsbruck
- Target Recruit Count
- 12
- Registration Number
- NCT02211742
- Locations
- 🇦🇹
Medical University Innsbruck, Department of Internal Medicine I, Innsbruck, Tirol, Austria
Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 24
- Registration Number
- NCT02113241
- Locations
- 🇲🇽
Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Phase III Insulin Add-On Asia Regional Program - ST
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 477
- Registration Number
- NCT02096705
- Locations
- 🇸🇬
Local Institution, Singapore, Singapore
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02060201
A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 60
- Registration Number
- NCT01877889
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT01662999
- Locations
- 🇺🇸
Icon Clinical Pharmacology, Omaha, Nebraska, United States
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 320
- Registration Number
- NCT01646320
- Locations
- 🇺🇸
Torrance Clinical Research Institute Inc., Lomita, California, United States
🇺🇸Diabetes Medical Center Of California, Northridge, California, United States
🇺🇸Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT01619059
- Locations
- 🇺🇸
Beach Physicians Clinical Research Corp., Huntington Beach, California, United States
🇺🇸Torrance Clinical Research, Lomita, California, United States
🇺🇸Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.